Efficacy and safety of entrectinib in patients with locally advanced/metastatic NTRK fusion-positive (NTRK-fp) solid tumours

被引：6

作者：

Bazhenova, L. ^{[1
]}

Liu, S. V. ^{[2
]}

Lin, J. J. ^{[3
]}

Lu, S. ^{[4
]}

Drilon, A. ^{[5
]}

Chawla, S. P. ^{[6
,7
]}

Fakih, M. ^{[8
]}

Krzakowski, M. ^{[9
]}

Paz-Ares, L. ^{[10
]}

Blakely, C. ^{[11
]}

Buchschacher, G. L., Jr. ^{[12
]}

Cassier, P. ^{[13
]}

Fan, Y. ^{[14
]}

Folprecht, G. ^{[15
]}

McCallum, S. ^{[16
]}

Pitcher, B. ^{[17
]}

Chen, D. ^{[18
]}

Freund, R. ^{[19
]}

Springfeld, C. ^{[20
]}

机构：

[1] Univ Calif San Diego, Moores Canc Ctr, Dept Med, San Diego, CA 92103 USA

[2] Georgetown Univ, Lombardi Comprehens Canc Ctr, Washington, DC USA

[3] Massachusetts Gen Hosp, Dept Hematol Oncol, Canc Ctr, Boston, MA 02114 USA

[4] Jiao Tong Univ, Shanghai Chest Hosp, Shanghai, Peoples R China

[5] Mem Sloan Kettering Canc Ctr, Dept Med, 1275 York Ave, New York, NY 10021 USA

[6] Weill Cornell Med Coll, New York, NY USA

[7] Sarcoma Oncol Ctr, Santa Monica, CA USA

[8] City Hope Comprehens Canc Ctr, Dept Med Oncol & Therapeut Res, Duarte, CA USA

[9] Maria Sklodowska Curie Inst, Dept Lung & Chest Canc, Ctr Oncol, Warsaw, Poland

[10] Univ Complutense Ciberonc, Hosp Univ 12 Octubre, Dept Med Oncol, CNIO H12o Lung Canc Clin Res Unit, Madrid, Spain

[11] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA

[12] Los Angeles Med Ctr, Dept Hematol Oncol, Kaiser Permanente Southern Calif, Los Angeles, CA USA

[13] Ctr Leon Berard, Dept Med, Lyon, France

[14] Zhejiang Canc Hosp, Med Dept Thorac Oncol, Hangzhou, Peoples R China

[15] Univ Hosp Carl Gustav Carus, Univ Canc Ctr, Med Dept Unit Med Oncol, Dresden, Germany

[16] Genentech Inc, Medicat Safety & Risk Management, San Francisco, CA 94080 USA

[17] F Hoffmann La Roche Ltd, Stat Sci, Mississauga, ON, Canada

[18] Genentech Inc, Clin Sci, San Francisco, CA 94080 USA

[19] F Hoffmann La Roche Ltd, Med Oncol, Basel, Switzerland

[20] Heidelberg Univ Hosp, Natl Ctr Tumor Dis, Dept Med Oncol, Heidelberg, Germany

来源：

ANNALS OF ONCOLOGY | 2021年 / 32卷

关键词：

D O I：

10.1016/j.annonc.2021.08.1055

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

533P

引用

页码：S598 / S599

页数：2

共 50 条

[1] Updated analysis of the efficacy and safety of entrectinib in patients (pts) with locally advanced/metastatic NTRK fusion-positive (NTRK-fp) solid tumors.
Krzakowski, Maciej Jerzy
Lu, Shun
Cousin, Sophie
Smit, Egbert F.
Springfeld, Christoph
Goto, Koichi
Garrido, Pilar
Chung, Christine H.
Lin, Jessica Jiyeong
Bray, Victoria J.
Pitcher, Bethany
Zeuner, Harald
Patel, Siddhartha
Bordogna, Walter
Gelderblom, Hans
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[2] Efficacy and safety of entrectinib in NTRK fusion-positive (NTRK-fp) breast cancer
Lu, Janice
Blakely, Collin M.
Le Tourneau, Christophe
Waqar, Saiama N.
Bauer, Todd M.
de Braud, Filippo
Hong, David S.
Spira, Alexander
Tan, Tira
McCallum, Samuel
Osborne, Stuart
Simmons, Brian
Barve, Minal
CANCER RESEARCH, 2021, 81 (04)
[3] Updated efficacy and safety of entrectinib in patients (pts) with NTRK fusion-positive (NTRK-fp) NSCLC
Cho, B. C.
Chiu, C-H.
Massarelli, E.
Chawla, S. P.
Buchschacher, G. L., Jr.
Goto, K.
Kim, S-W.
Overbeck, T. R.
Loong, H. H. F.
Chee, C. E.
Garrido, P.
Heinzmann, S.
Pitcher, B.
John, T.
ANNALS OF ONCOLOGY, 2022, 33 : S82 - S83
[4] Updated efficacy and safety data of entrectinib in patients (pts) with locally advanced/metastatic NTRK fusion-positive (fp) solid tumours
Lu, S.
De Braud, F. G. M.
Fan, Y.
Hu, X.
Ohe, Y.
Yu, Y.
Ahn, M-J.
Cassier, P.
Lin, J. J.
Paz-Ares, L.
Xue, C.
Bordogna, W.
Patel, S.
Zeuner, H.
Dong, X.
ANNALS OF ONCOLOGY, 2023, 34 : S468 - S469
[5] Entrectinib in Japanese patients (pts) with locally advanced/metastatic ROS1 fusion-positive (fp) NSCLC and NTRK-fp solid tumours
Murakami, H.
Ohe, Y.
Hayashi, H.
Esaki, T.
Yamaguchi, T.
Fukuhara, T.
Daga, H.
Tanaka, H.
Kozuki, T.
Osborne, S.
Bordogna, W.
Goto, K.
ANNALS OF ONCOLOGY, 2022, 33 : S1594 - S1594
[6] Entrectinib in Chinese (mainland China, Hong Kong, Taiwan) patients (pts) with locally advanced/metastatic ROS1 fusion-positive (fp) NSCLC and NTRK-fp solid tumours
Lu, S.
Chiu, C-H.
Yu, Y.
Loong, H. H. F.
Lin, C. C.
Hu, X.
Dong, X.
Li, J.
Zhao, J.
Ye-Hui, S.
Zhang, Z.
Zhao, N.
Xia, J.
Wang, D.
Fan, Y.
ANNALS OF ONCOLOGY, 2022, 33 : S83 - S84
[7] Efficacy and safety of entrectinib in patients (pts) with NTRK-fusion positive (NTRK-fp) solid tumors: An updated integrated analysis.
Rolfo, Christian Diego
De Braud, Filippo G.
Doebele, Robert Charles
Drilon, Alexander E.
Siena, Salvatore
Patel, Manish
Cho, Byoung Chul
Liu, Stephen, V
Myung-Ju Ahn
Chiu, Chao-Hua
Farago, Anna F.
Goto, Koichi
Lee, Jeeyun
Bazhenova, Lyudmila
John, Tom
Fakih, Marwan
Simmons, Brian P.
Pitcher, Bethany
Huang, Xinhui
Demetri, George D.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[8] Efficacy and safety of entrectinib in an Asian population with NTRK fusion-positive (fp) solid tumours or ROS1-fp NSCLC
Tan, D. S. W.
Ahn, M-J.
Chiu, C-H.
Ohe, Y.
Loong, H. H. F.
Chee, C. E.
Kim, S-W.
Takeda, M.
Li, Y-C.
Cheng, A.
Hida, T.
Kim, D-W.
Nogami, N.
Su, W-C.
Tanaka, H.
Osborne, S.
Freund, R.
Chen, D.
Seto, T.
ANNALS OF ONCOLOGY, 2020, 31 : S1358 - S1359
[9] Entrectinib in NTRK fusion-positive (NTRK-fp) breast cancer: Updated data from STARTRK-2
Lu, J.
Blakely, C. M.
Barve, M.
Chung, C. H.
Waqar, S. N.
Hu, X.
Delord, J-P.
Krzakowski, M. J.
Yonemori, K.
Chen, D. T.
Klingbiel, D.
Heinzmann, S.
Le Tourneau, C.
ANNALS OF ONCOLOGY, 2022, 33 : S204 - S205
[10] Intracranial efficacy of entrectinib in patients with NTRK fusion-positive solid tumours and baseline CNS metastases
John, T.
Chiu, C-H.
Cho, B. C.
Fakih, M.
Farago, A. F.
Demetri, G. D.
Goto, K.
Doebele, R. C.
Siena, S.
Drilon, A.
Patel, M. R.
Liu, S. V.
Ahn, M-J.
Bazhenova, L.
Overbeck, T. R.
Nieva, J.
Kim, S-W.
Veronese, L.
Day, B-M.
De Braud, F.
ANNALS OF ONCOLOGY, 2020, 31 : S397 - S398

← 1 2 3 4 5 →